David Paul Keenan - 17 Oct 2025 Form 3 Insider Report for AMARIN CORP PLC\UK (AMRN)

Role: EVP, Chief Operating Officer
Signature: /s/ Jonathan Provoost, by power of attorney
Issuer symbol: AMRN
Transactions as of: 17 Oct 2025
Net transactions value: $0
Form type: 3
Filing time: 31 Oct 2025, 16:30:06 UTC
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Keenan David Paul	EVP, Chief Operating Officer	C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER	/s/ Jonathan Provoost, by power of attorney	31 Oct 2025	0002094574

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMRN	American Depositary Share						7,950	17 Oct 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMRN	Restricted Stock Units							17 Oct 2025	American Depositary Share	6,740	$0.000000	Direct	F1, F2, F3, F4
holding	AMRN	Restricted Stock Units							17 Oct 2025	American Depositary Share	5,800	$0.000000	Direct	F1, F2, F4, F5
holding	AMRN	Restricted Stock Units							17 Oct 2025	American Depositary Share	7,376	$0.000000	Direct	F1, F2, F4, F6
holding	AMRN	Stock Option (Right to Buy)							17 Oct 2025	American Depositary Share	33,193	$12.40	Direct	F1, F7, F8
holding	AMRN	Stock Option (Right to Buy)							17 Oct 2025	American Depositary Share	20,900	$24.20	Direct	F1, F8, F9
holding	AMRN	Stock Option (Right to Buy)							17 Oct 2025	American Depositary Share	13,480	$36.00	Direct	F1, F8, F10
holding	AMRN	Stock Option (Right to Buy)							17 Oct 2025	American Depositary Share	5,000	$29.00	Direct	F1, F8, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 3 reflect the ADS Ratio Change.
F2	Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
F3	On February 21, 2023, the Reporting Person was granted 6,740 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F4	Not applicable.
F5	On February 1, 2024, the Reporting Person was granted 5,800 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2025, January 31, 2026 and January 31, 2027.
F6	On January 10, 2025, the Reporting Person was granted 7,376 RSUs under the Plan. These RSUs vest over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
F7	On January 10, 2025, the Reporting Person was granted an option to purchase 33,193 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
F8	Grant price is set at the higher of (1) our nominal par value of 50 pence per share, as converted on date of grant, for which our Plan dictates under United Kingdom law, or (2) fair market value of stock price on the NASDAQ at close of business day.
F9	On February 1, 2024, the Reporting Person was granted an option to purchase 20,900 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
F10	On February 21, 2023, the Reporting Person was granted an option to purchase 13,480 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
F11	On June 1, 2022, the Reporting Person was granted an option to purchase 5,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each April, July, October and January.